New imaging combo could sharpen prostate cancer radiation

NCT ID NCT03734757

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether combining PET-CT and MRI scans (called trimodality imaging) can better define the target area for radiotherapy in high-risk prostate cancer. Twenty patients received both standard scans and the new combined scan before treatment. Researchers compared the volumes drawn for radiation planning to see if the new method changes the treatment approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this imaging approach could help doctors more precisely target radiotherapy for high-risk prostate cancer, potentially improving outcomes.

What could go wrong

This is a very small, early study (20 participants) focused on imaging comparisons, not treatment outcomes. It may not lead to changes in standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, 76038, France